2023
ScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis
Mann J, Lucca L, Austin M, Merkin R, Robert M, Al Bawardy B, Raddassi K, Aizenbud L, Joshi N, Hafler D, Abraham C, Herold K, Kluger H. ScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis. Journal For ImmunoTherapy Of Cancer 2023, 11: e007358. PMID: 37586769, PMCID: PMC10432652, DOI: 10.1136/jitc-2023-007358.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsT cell subsetsCheckpoint inhibitorsImmune environmentImmune checkpoint inhibitor-induced colitisCheckpoint inhibitor-induced colitisPeripheral immune environmentsStages of colitisTreatment of colitisMerkel cell carcinomaT cell populationsPeripheral blood samplesCourse of progressionT cell receptorMultiple tumor typesAlternative cancer therapyCommon toxicitiesICI colitisTreatment discontinuationAdverse eventsBiologic therapyImmune suppressionCell carcinomaColitisBlood samplesOutcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays
Al-Bawardy B, Jenkins S, Snyder M, Frinack J, Ladwig P, Loftus E, Willrich M. Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays. Clinical Biochemistry 2023, 119: 110618. PMID: 37507083, DOI: 10.1016/j.clinbiochem.2023.110618.Peer-Reviewed Original ResearchConceptsInflammatory bowel disease patientsBowel disease patientsEndoscopic healingClinical remissionDisease patientsMcg/Normal serum C-reactive proteinDrug monitoringSerum C-reactive proteinLC-MS/MSInfliximab drug levelsFavorable clinical outcomeC-reactive proteinTherapeutic drug monitoringIBD patientsNormal CRPClinical outcomesDrug levelsPatientsECLIARemissionDifferent assaysOutcomesMcgAssaysOral Vancomycin Induced and Maintained Clinical and Endoscopic Remission in Ulcerative Colitis and Primary Sclerosing Cholangitis Post-liver Transplantation
Almomen H, Al-Bawardy B. Oral Vancomycin Induced and Maintained Clinical and Endoscopic Remission in Ulcerative Colitis and Primary Sclerosing Cholangitis Post-liver Transplantation. Inflammatory Bowel Diseases 2023, 29: 837-838. PMID: 36888548, DOI: 10.1093/ibd/izad040.Peer-Reviewed Original ResearchAssessment of Inflammatory Bowel Disease Training Among Gastroenterology Fellows
Al-Bawardy B, Malter L, Ehrlich A, Rieder F, Gaidos J, Proctor D, Windish D. Assessment of Inflammatory Bowel Disease Training Among Gastroenterology Fellows. Inflammatory Bowel Diseases 2023, 29: 1990-1992. PMID: 36810663, PMCID: PMC11491607, DOI: 10.1093/ibd/izad030.Peer-Reviewed Original ResearchOutcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease
Sayed A, Assis D, Silveira M, Deng Y, Ciarleglio M, Gaidos J, Proctor D, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. European Journal Of Gastroenterology & Hepatology 2023, 35: 270-274. PMID: 36708297, DOI: 10.1097/meg.0000000000002510.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisInflammatory bowel diseasePSC-IBDEndoscopic healingTherapy groupAdvanced therapiesClinical remissionBowel diseaseAcute ascending cholangitisRate of cholangitisSmall bowel involvementThird of patientsAscending cholangitisSclerosing cholangitisAdult patientsBowel involvementSecondary outcomesMedian agePrimary outcomeRetrospective studyHigh riskCholangitisPatientsTherapyLarger studyComparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study
Holmer A, Luo J, Russ K, Park S, Yang J, Ertem F, Dueker J, Nguyen V, Hong S, Zenger C, Axelrad J, Sofia A, Petrov J, Al-Bawardy B, Fudman D, Llano E, Dailey J, Jangi S, Khakoo N, Damas O, Barnes E, Scott F, Ungaro R, Singh S, Helping-IBD R. Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study. Clinical Gastroenterology And Hepatology 2023, 21: 1598-1606.e5. PMID: 36642291, DOI: 10.1016/j.cgh.2023.01.002.Peer-Reviewed Original ResearchConceptsNon-TNF biologicsInflammatory bowel diseaseProgression-free survivalRecurrence-free survivalTNFα antagonistsActive cancerPrior cancerCohort studyBiologic agentsBowel diseaseRecent cancerMulticenter retrospective cohort studyMulti-center cohort studyIBD disease severityRetrospective cohort studyChoice of biologicsTumor necrosis factorCohort BPrimary outcomeComparable safetyΑ antagonistsComparative safetyCancer recurrenceNecrosis factorPatients
2021
Immune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies
Tran AN, Wang M, Hundt M, Chugh R, Ohm J, Grimshaw A, Ciarleglio M, Hung KW, Proctor DD, Price CC, Laine L, Al-Bawardy B. Immune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies. Journal Of Immunotherapy 2021, 44: 325-334. PMID: 34380976, DOI: 10.1097/cji.0000000000000383.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsDiarrhea/colitisICI therapyCheckpoint inhibitorsObservational studyAnti-programmed cell death-1/Outcomes of ICISystematic reviewCell death-1/Permanent ICI discontinuationReal-world incidenceRemission of diarrheaRecurrence of symptomsDeath-1/Treatment of diarrheaRandom-effects modelICI discontinuationAdvanced malignanciesAppropriate patientsPrimary outcomeOverall incidenceAntigen-4Early treatmentColitisHigh risk
2020
Cutaneous Vasculitis After Ustekinumab Induction in Crohn’s Disease
Chugh R, Proctor DD, Little A, Myung P, Cowper S, Imaeda S, Pashankar DS, Al-Bawardy B. Cutaneous Vasculitis After Ustekinumab Induction in Crohn’s Disease. Inflammatory Bowel Diseases 2020, 27: e30-e31. PMID: 33179735, DOI: 10.1093/ibd/izaa285.Peer-Reviewed Case Reports and Technical NotesThe Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Ramos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflammatory Bowel Diseases 2020, 27: 1270-1276. PMID: 33165569, DOI: 10.1093/ibd/izaa293.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseExtraintestinal manifestationsPeripheral arthritisBowel diseaseDose of vedolizumabPrevious biologic useMulticenter retrospective studyCurrent medical therapyTerms of ageConcurrent immunosuppressantsCorticosteroid therapyVDZ treatmentIBD subtypesBiologic useSecondary outcomesMedical therapyPrimary outcomeClinical outcomesMulticenter studyRetrospective studyVedolizumabPatientsCommon typeDiscontinuationArthritisThe emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
Damsky W, Peterson D, Ramseier J, Al-Bawardy B, Chun H, Proctor D, Strand V, Flavell RA, King B. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. Journal Of Allergy And Clinical Immunology 2020, 147: 814-826. PMID: 33129886, DOI: 10.1016/j.jaci.2020.10.022.BooksConceptsTranscription pathwayDownstream Janus kinaseJAK-signal transducerSmall molecule inhibitorsSignal transducerJanus kinaseJAK inhibitorsAutoimmune/inflammatory disordersKinase inhibitorsActivatorPathwayInhibitorsCytokine activityInflammatory diseasesImmune systemKinaseOrgan systemsBiologyCytokinesTransducerInhibitionUpper gastrointestinal bleeding: Causes and patient outcomes
Almadi MA, Almutairdi A, Alruzug IM, Aldarsouny TA, Semaan T, Aldaher MK, AlMustafa A, Azzam N, Batwa F, Albawardy B, Aljebreen A. Upper gastrointestinal bleeding: Causes and patient outcomes. Saudi Journal Of Gastroenterology 2020, 27: 20-27. PMID: 33047678, PMCID: PMC8083248, DOI: 10.4103/sjg.sjg_297_20.Peer-Reviewed Original ResearchConceptsUpper gastrointestinal bleedingIntensive care unitPre-endoscopic Rockall scoreRockall scoreICU admissionHemodynamic statusCare unitPatient outcomesMortality rateCauses of UGIBPrior upper gastrointestinal bleedingTertiary care university hospitalHospital mortality rateCare university hospitalPatient's hemodynamic statusPeptic ulcer diseaseImportant patient outcomesPast medical conditionsHospital mortalityNonvariceal sourcesGastrointestinal bleedingLaboratory characteristicsConsiderable morbidityEsophageal varicesUlcer diseaseSARS-CoV-2 Infection and Dual-Biologic Therapy for Crohn’s Disease
Dimopoulos C, Al-Bawardy B. SARS-CoV-2 Infection and Dual-Biologic Therapy for Crohn’s Disease. Inflammatory Bowel Diseases 2020, 26: e153-e154. PMID: 33043966, PMCID: PMC7665493, DOI: 10.1093/ibd/izaa275.Peer-Reviewed Case Reports and Technical Notes
2019
Prospective multicenter study to evaluate capsule endoscopy competency using a validated assessment tool
Rajan E, Martinez M, Gorospe E, Al Bawardy B, Dobashi A, Mara KC, Hansel SL, Bruining DH, Murray JA, Leggett CL, Nehra V, Iyer PG, Pasha SF, Leighton JA, Shiff AD, Gurudu SR, Raffals LE, Lavey C, Katzka DA, Chen CH. Prospective multicenter study to evaluate capsule endoscopy competency using a validated assessment tool. Gastrointestinal Endoscopy 2019, 91: 1140-1145. PMID: 31883863, DOI: 10.1016/j.gie.2019.12.024.Peer-Reviewed Original ResearchPatient-oriented education and visual-aid intervention are inadequate to identify patients with potential capsule retention: a prospective randomized study
Al-Bawardy B, Kamboj AK, Desai S, Gorospe E, Bruining DH, Gostout CJ, Hansel SL, Larson MV, Murray JA, Nehra V, Leggett CL, Szarka LA, Watson RE, Rajan E. Patient-oriented education and visual-aid intervention are inadequate to identify patients with potential capsule retention: a prospective randomized study. Scandinavian Journal Of Gastroenterology 2019, 54: 662-665. PMID: 31034255, DOI: 10.1080/00365521.2019.1608465.Peer-Reviewed Original ResearchConceptsPatient-oriented educationVideo capsule endoscopyCapsule passageWB groupCapsule retentionProcedure-related risksSignificant differencesLack of visualizationBACKGROUND/Information bookletPatientsVerbal educationCapsule endoscopyStudy teamWrist bandInterventionGroupStatusPOE groupEndoscopyPoor indicatorAid interventionsDifferences
2018
Findings of CT-Derived Bone Strength Assessment in Inflammatory Bowel Disease Patients Undergoing CT Enterography in Clinical Practice
Maldonado FJ, Al Bawardy BF, Nehra AK, Lee YS, Bruining DH, Adkins MC, Keaveny TM, Johnson MP, Fidler JL, McCollough CH, Fletcher JG. Findings of CT-Derived Bone Strength Assessment in Inflammatory Bowel Disease Patients Undergoing CT Enterography in Clinical Practice. Inflammatory Bowel Diseases 2018, 25: 1072-1079. PMID: 30476314, DOI: 10.1093/ibd/izy341.Peer-Reviewed Original ResearchConceptsBiomechanical CT analysisBone mineral densityHigh fracture riskHigh-risk groupFracture riskCT enterographyIBD patientsFemoral neck bone mineral densityInflammatory bowel disease patientsNeck bone mineral densityWorld Health Organization classificationConsecutive IBD patientsFracture risk classificationBowel disease patientsFindings of CTMetabolic bone diseaseRetrospective reviewClinical featuresExact prevalenceDisease patientsOrganization classificationMineral densityBone diseasePatientsClinical practiceVedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease
Al-Bawardy B, Ramos GP, Willrich MAV, Jenkins SM, Park SH, Aniwan S, Schoenoff SA, Bruining DH, Papadakis KA, Raffals L, Tremaine WJ, Loftus EV. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018, 25: 580-586. PMID: 30165638, DOI: 10.1093/ibd/izy272.Peer-Reviewed Original ResearchConceptsMedian vedolizumab trough levelsVedolizumab trough levelsC-reactive proteinInflammatory bowel diseaseNormal C-reactive proteinMucosal healingCrohn's diseaseUC patientsBowel diseaseTrough levelsUlcerative colitisClinical managementFourth of patientsTrough level measurementMayo endoscopic scoreCross-sectional studyHigh CRP patientsBiomarker normalizationIBD patientsClinical remissionCRP patientsEndoscopic scoreMucosal ulcersDetectable antibodiesBACKGROUND/Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
Ramos GP, Stroh G, Al-Bawardy B, Faubion WA, Papadakis KA, Escalante P. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. Inflammatory Bowel Diseases 2018, 24: 2272-2277. PMID: 29718223, DOI: 10.1093/ibd/izy133.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsBiological TherapyColitis, UlcerativeCrohn DiseaseFemaleFollow-Up StudiesGastrointestinal AgentsHumansInterferon-gamma Release TestsLatent TuberculosisMaleMycobacterium tuberculosisPrognosisProspective StudiesRetrospective StudiesTreatment OutcomeTuberculin TestConceptsLatent tuberculosis infectionInflammatory bowel diseaseTuberculin skin testBiologic therapyLTBI treatmentIBD patientsTuberculosis reactivationBowel diseaseTuberculosis infectionLTBI treatment regimenReactivation of TBRisk of reactivationInterferon-gamma releaseOutcome of treatmentStudy inclusion criteriaMedian annual riskAdalimumab monotherapyIsoniazid therapyTB reactivationCertolizumab pegolPrimary outcomeRetrospective reviewTreatment regimenMedian timeGamma releaseOutcomes of endoscopic intervention for overt GI bleeding in severe thrombocytopenia
Ramos GP, Binder M, Hampel P, Braga Neto MB, Sunjaya D, Al Bawardy B, Abu Dayyeh BK, Buttar NS, Bruining DH, Prabhu-Coelho N, Larson MV, Wong Kee Song LM, Rajan E. Outcomes of endoscopic intervention for overt GI bleeding in severe thrombocytopenia. Gastrointestinal Endoscopy 2018, 88: 55-61. PMID: 29408558, DOI: 10.1016/j.gie.2018.01.028.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCause of DeathCohort StudiesComorbidityEndoscopy, GastrointestinalErythrocyte TransfusionFemaleGastrointestinal HemorrhageHematemesisHemostasis, SurgicalHumansHypotensionIntensive Care UnitsInternational Normalized RatioLiver CirrhosisLung DiseasesMaleMelenaMiddle AgedMortalityPartial Thromboplastin TimePlatelet TransfusionRecurrenceRetrospective StudiesRisk FactorsSeverity of Illness IndexThrombocytopeniaYoung AdultConceptsIncreased international normalized ratioOvert gastrointestinal bleedingInitial hemostasis rateRecurrent bleeding rateGastrointestinal bleedingLiver cirrhosisSevere thrombocytopeniaPlatelet transfusionsPlatelet countTherapeutic yieldRecurrent bleedingHemostasis rateAdverse eventsBleeding rateHigh initial hemostasis rateIntensive care unit admissionCare unit admissionPredictors of mortalityCause mortality ratesMedian platelet countHours of presentationInternational normalized ratioSetting of thrombocytopeniaProcedural adverse eventsPartial thromboplastin timeUncommon Cause of Abdominal Pain, Nausea, and Vomiting
Al-Bawardy B, Hansel SL. Uncommon Cause of Abdominal Pain, Nausea, and Vomiting. Clinical Gastroenterology And Hepatology 2018, 17: e21. PMID: 29360508, DOI: 10.1016/j.cgh.2018.01.015.Peer-Reviewed Case Reports and Technical Notes
2017
Endoscopic and Radiographic Assessment of Crohn's Disease
Al-Bawardy B, Hansel SL, Fidler JL, Barlow JM, Bruining DH. Endoscopic and Radiographic Assessment of Crohn's Disease. Gastroenterology Clinics Of North America 2017, 46: 493-513. PMID: 28838411, DOI: 10.1016/j.gtc.2017.05.005.BooksConceptsCrohn's diseaseFavorable long-term outcomeEndoscopic mucosal healingRadiologic scoring systemChronic inflammatory disordersLong-term outcomesObjective measuresRadiologic responseDisease activityClinical improvementMucosal healingClinical symptomsReduced hospitalizationsInflammatory disordersRadiographic assessmentTreatment targetsScoring systemScoring toolDiseaseMore objective measuresTherapyCorticosteroidsHospitalizationComplicationsInflammation